Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.
Menu

Korro Bio Inc (KRRO)

Korro Bio Inc (KRRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Korro to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Aug 27, 6:00AM CDT

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform...

KRRO : 12.24 (-2.00%)
Korro to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Aug 27, 6:00AM CDT

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Aug 14, 3:05PM CDT

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Aug 14, 3:05PM CDT

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform...

KRRO : 12.24 (-2.00%)
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Thu Aug 6, 6:00AM CDT

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jul 10, 3:05PM CDT

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide...

KRRO : 12.24 (-2.00%)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jul 10, 3:05PM CDT

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ® ) platform...

KRRO : 12.24 (-2.00%)
Korro to Present at the 2026 Jefferies Global Healthcare Conference GlobeNewswire - Wed May 27, 6:00AM CDT

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform...

KRRO : 12.24 (-2.00%)
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire - Tue May 19, 6:00AM CDT

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1...

KRRO : 12.24 (-2.00%)
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire - Tue May 19, 6:00AM CDT

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the...

KRRO : 12.24 (-2.00%)

Barchart Exclusives

3 Top Dividend Stocks to Buy in September Barchart - Tue Sep 1, 6:30PM CDT
Chevron, Realty Income, and NextEra bring more than just yield to the table. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.